Eliminating the need of serum testing using low serum culture conditions for human bone marrow-derived mesenchymal stromal cell expansion

BioMedical Engineering Online

Volumn 12, Issue 1, 2013, Pages

  Wappler, Jessica ^a   Rath, Björn ^a   Läufer, Tanja ^a   Heidenreich, Axel ^a   Montzka, Katrin ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Cytotoxicity; Mesenchymal stromal cells; MSC tested serum; Proliferation; Serum reduced medium

Indexed keywords

CLINICAL INVESTIGATION; CULTURE CONDITIONS; FETAL BOVINE SERUM; MESENCHYMAL STROMAL CELLS; MSC-TESTED SERUM; PROLIFERATION; SERUM CONCENTRATION; SERUM-REDUCED MEDIUM;

BONE; CELL DEATH; CELL PROLIFERATION; CYTOTOXICITY; OPTIMIZATION; STEM CELLS; TISSUE ENGINEERING;

BODY FLUIDS;

BOVINAE;

ANIMAL; ARTICLE; BONE MARROW; CATTLE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMISTRY; CULTURE MEDIUM; CULTURE TECHNIQUE; CYTOLOGY; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM; METHODOLOGY; PHYSIOLOGY; SERUM; TISSUE ENGINEERING;

ANIMALS; BONE MARROW; CATTLE; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CULTURE MEDIA; HUMANS; MESENCHYMAL STROMAL CELLS; SERUM; TISSUE ENGINEERING;

MLCS; MLOWN;

EID: 84873978928     PISSN: None     EISSN: 1475925X     Source Type: Journal    
DOI: 10.1186/1475-925X-12-15     Document Type: Article

References (28)

1. Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Alwayn IP, Weimar W, Hoogduijn MJ. Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation 2009, 87:896-906.
2. Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J, Haynesworth SE, Koc ON. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004, 33:597-604.
3. Horwitz EM, Prockop DJ, Gordon PL, Koo WW, Fitzpatrick LA, Neel MD, McCarville ME, Orchard PJ, Pyeritz RE, Brenner MK. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001, 97:1227-1231.
4. Le Blanc K, Gotherstrom C, Ringden O, Hassan M, McMahon R, Horwitz E, Anneren G, Axelsson O, Nunn J, Ewald U, et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005, 79:1607-1614.
5. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, Sun JP. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004, 94:92-95.
6. Hughey CC, Johnsen VL, Ma L, James FD, Young PP, Wasserman DH, Rottman JN, Hittel DS, Shearer J. Mesenchymal stem cell transplantation for the infarcted Heart: a role in minimizing abnormalities in cardiac-specific energy metabolism. Am J Physiol Endocrinol Metab 2012, 302(2):E163-E172.
7. Moviglia GA, Fernandez Vina R, Brizuela JA, Saslavsky J, Vrsalovic F, Varela G, Bastos F, Farina P, Etchegaray G, Barbieri M, et al. Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients. Cytotherapy 2006, 8:202-209.
8. Sykova E, Homola A, Mazanec R, Lachmann H, Konradova SL, Kobylka P, Padr R, Neuwirth J, Komrska V, Vavra V, et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant 2006, 15:675-687.
9. Liang J, Zhang H, Hua B, Wang H, Wang J, Han Z, Sun L. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult Scler 2009, 15:644-646.
10. Ra JC, Kang SK, Shin IS, Park HG, Joo SA, Kim JG, Kang BC, Lee YS, Nakama K, Piao M, et al. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med 2011, 9:181.
11. Prather WR, Toren A, Meiron M, Ofir R, Tschope C, Horwitz EM. The role of placental-derived adherent stromal cell (PLX-PAD) in the treatment of critical limb ischemia. Cytotherapy 2009, 11:427-434.
12. Guiducci S, Porta F, Saccardi R, Guidi S, Ibba-Manneschi L, Manetti M, Mazzanti B, Dal Pozzo S, Milia AF, Bellando-Randone S, et al. Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report. Ann Intern Med 2010, 153:650-654.
13. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006, 8:315-317.
14. Horwitz EM, Prather WR. Cytokines as the major mechanism of mesenchymal stem cell clinical activity: expanding the spectrum of cell therapy. Isr Med Assoc J 2009, 11:209-211.
15. Montzka K, Fuhrmann T, Muller-Ehmsen J, Woltje M, Brook GA. Growth factor and cytokine expression of human mesenchymal stromal cells is not altered in an in vitro model of tissue damage. Cytotherapy 2010, 12:870-880.
16. Neuhuber B, Timothy Himes B, Shumsky JS, Gallo G, Fischer I. Axon growth and recovery of function supported by human bone marrow stromal cells in the injured spinal cord exhibit donor variations. Brain Res 2005, 1035:73-85.
17. Fuhrmann T, Montzka K, Hillen LM, Hodde D, Dreier A, Bozkurt A, Woltje M, Brook GA. Axon growth-promoting properties of human bone marrow mesenchymal stromal cells. Neurosci Lett 2010, 474:37-41.
18. Chen X, Katakowski M, Li Y, Lu D, Wang L, Zhang L, Chen J, Xu Y, Gautam S, Mahmood A, Chopp M. Human bone marrow stromal cell cultures conditioned by traumatic brain tissue extracts: growth factor production. J Neurosci Res 2002, 69:687-691.
19. Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol 2009, 217:318-324.
20. Fibbe WE, Noort WA. Mesenchymal stem cells and hematopoietic stem cell transplantation. Ann N Y Acad Sci 2003, 996:235-244.
21. Shahdadfar A, Fronsdal K, Haug T, Reinholt FP, Brinchmann JE. In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells 2005, 23:1357-1366.
22. Tekkatte C, Gunasingh GP, Cherian KM, Sankaranarayanan K. " Humanized" stem cell culture techniques: the animal serum controversy. Stem Cells Int 2011, 504723.
23. Montzka K, Fuhrmann T, Woltje M, Brook GA. Expansion of human bone marrow-derived mesenchymal stromal cells: serum-reduced medium is better than conventional medium. Cytotherapy 2010, 12:587-592.
24. Montzka K, Lassonczyk N, Tschoke B, Neuss S, Fuhrmann T, Franzen R, Smeets R, Brook GA, Woltje M. Neural differentiation potential of human bone marrow-derived mesenchymal stromal cells: misleading marker gene expression. BMC Neurosci 2009, 10:16.
25. Furue MK, Na J, Jackson JP, Okamoto T, Jones M, Baker D, Hata R, Moore HD, Sato JD, Andrews PW. Heparin promotes the growth of human embryonic stem cells in a defined serum-free medium. Proc Natl Acad Sci U S A 2008, 105:13409-13414.
26. Mimura S, Kimura N, Hirata M, Tateyama D, Hayashida M, Umezawa A, Kohara A, Nikawa H, Okamoto T, Furue MK. Growth factor-defined culture medium for human mesenchymal stem cells. Int J Dev Biol 2011, 55:181-187.
27. Chase LG, Lakshmipathy U, Solchaga LA, Rao MS, Vemuri MC. A novel serum-free medium for the expansion of human mesenchymal stem cells. Stem Cell Res Ther 2010, 1:8.
28. Lohmann M, Walenda G, Hemeda H, Joussen S, Drescher W, Jockenhoevel S, Hutschenreuter G, Zenke M, Wagner W. Donor age of human platelet lysate affects proliferation and differentiation of mesenchymal stem cells. PLoS One 2012, 7(5):e37839.